Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Heinemann

Showing results (11-20 of 384) with videos related to

Pageof 39
Sort By:
MMW Fortschritte Der Medizin|October 20, 2007
[Neoadjuvant and adjuvant therapies for solid tumours]Volker Heinemann, Nicolas Moosmann
Future Oncology (London, England)|February 5, 2008
The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancerStefan Boeck, Volker Heinemann
Expert Opinion on Biological Therapy|January 26, 2007
Cetuximab in the treatment of metastatic colorectal cancerNicolas Moosmann, Volker Heinemann
Oncology|November 20, 2010
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancerVolker Heinemann, Paulo M Hoff
Deutsche Medizinische Wochenschrift (1946)|September 25, 2015
[Use of tumor markers as screening tools - sense or nonsense?]Dominik Paul Modest, Volker Heinemann
The Oncologist|July 11, 2008
Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challengeHans-Joachim Stemmler, Volker Heinemann
Anticancer Research|December 1, 2010
Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinomaWolfram C M Dempke, Volker Heinemann
European Journal of Cancer (Oxford, England : 1990)|January 7, 2009
Resistance to EGF-R (erbB-1) and VEGF-R modulating agentsWolfram C M Dempke, Volker Heinemann
Visceral Medicine|August 6, 2016
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesJulian Holch, Sebastian Stintzing, Volker Heinemann
The Lancet. Oncology|May 3, 2019
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studiesDan Aderka, Sebastian Stintzing, Volker Heinemann
Pageof 39

Showing results (11-20 of 384) with videos related to

Sort By:
Pageof 39
MMW Fortschritte Der Medizin|October 20, 2007
[Neoadjuvant and adjuvant therapies for solid tumours]Volker Heinemann, Nicolas Moosmann
Future Oncology (London, England)|February 5, 2008
The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancerStefan Boeck, Volker Heinemann
Expert Opinion on Biological Therapy|January 26, 2007
Cetuximab in the treatment of metastatic colorectal cancerNicolas Moosmann, Volker Heinemann
Oncology|November 20, 2010
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancerVolker Heinemann, Paulo M Hoff
Deutsche Medizinische Wochenschrift (1946)|September 25, 2015
[Use of tumor markers as screening tools - sense or nonsense?]Dominik Paul Modest, Volker Heinemann
The Oncologist|July 11, 2008
Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challengeHans-Joachim Stemmler, Volker Heinemann
Anticancer Research|December 1, 2010
Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinomaWolfram C M Dempke, Volker Heinemann
European Journal of Cancer (Oxford, England : 1990)|January 7, 2009
Resistance to EGF-R (erbB-1) and VEGF-R modulating agentsWolfram C M Dempke, Volker Heinemann
Visceral Medicine|August 6, 2016
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesJulian Holch, Sebastian Stintzing, Volker Heinemann
The Lancet. Oncology|May 3, 2019
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studiesDan Aderka, Sebastian Stintzing, Volker Heinemann
Pageof 39